English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  51655167    Online Users :  880
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"lu l c"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 31-55 of 144  (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-02-07T07:49:00Z Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏 2022-02-07T07:49:00Z Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; SUNG-HSIN KUO; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2022-02-07T03:29:05Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU
臺大學術典藏 2022-02-07T03:29:04Z Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU
臺大學術典藏 2022-02-07T03:29:03Z Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; CHIH-HUNG HSU; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏 2022-02-07T03:29:02Z Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance Wang Y.; Lu L.-C.; Guan Y.; Ho M.-C.; Lu S.; Spahn J.; CHIH-HUNG HSU
臺大學術典藏 2022-01-12T07:07:09Z Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience Wang Y.-W.; Tsai X.C.-H.; HSIN-AN HOU; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏 2022-01-05T03:36:40Z Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏 2022 ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis Lu L.-C.; Deantonio C.; Palu C.C.; Lee Y.-H.; Mitchell L.S.; Cowan M.; Corser M.; Sherry L.; Cheng A.-L.; Quaratino S.; Shao Y.-Y.; Sainson R.C.A.; CHIH-HUNG HSU
臺大學術典藏 2022 Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU; Hsu C.; Lin Z.-Z.; Lu L.-C.; Chen B.-B.; Liang P.-C.; Shih T.T.-F.; Liu T.-H.; Shen Y.-C.
臺大學術典藏 2021-09-01T01:54:09Z Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy Shao Y.-Y.; Lu L.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-09-01T01:53:57Z Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-09-01T01:53:55Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:53:49Z Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏 2021-09-01T01:53:42Z Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:28Z �]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-08-31T06:42:23Z Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:21Z Recent advances in the prevention of hepatocellular carcinoma recurrence Lu L.-C.; ANN-LII CHENG; Poon R.T.P.
臺大學術典藏 2021-08-31T06:42:19Z Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:44Z Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:42Z Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma Lin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:37Z Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:29Z Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma Chang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:24Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-08-31T06:29:23Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG

Showing items 31-55 of 144  (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page